Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Ivantis, Inc. Announces HYDRUS II Glaucoma Study Met Primary Endpoint In A Randomized Controlled Trial At Two Years

October 21, 2014 – 5:00 am | Edit Post

IRVINE, Calif.–(BUSINESS WIRE)–Ivantis, Inc., developer of the novel Hydrus Microstent, an investigational device designed to lower eye pressure in patients with open angle glaucoma, today announced that the international HYDRUS II trial met its primary endpoint by a wide margin. Results of the randomized, controlled study showed that the Hydrus Microstent, a minimally invasive glaucoma surgery…

Allergan Inc. Chops Jobs In Carlsbad

October 21, 2014 – 5:00 am | Edit Post

Aptose Biosciences Announces Approval For Listing On The Capital Market Shares To Begin Trading Under The Symbol APTO

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO and TORONTO, Oct. 21, 2014 /PRNewswire/ – Aptose Biosciences Inc. (Aptose) (TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, announced today that its common shares…

Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO and TORONTO, Oct. 21, 2014 /PRNewswire/ – Aptose Biosciences Inc.
(Aptose) (TSX:APS), a clinical-stage company developing targeted agents
and molecular diagnostics to treat the underlying mechanisms of cancer,
announced today that its common shares have been approved for listing
on the NASDAQ Capital Market under the symbol “APTO”.

Aptose will begin trading on NASDAQ on or around October 23, 2014. The
Company will retain its listing on the Toronto Stock Exchange under the
symbol “APS”.

“Our listing on the NASDAQ Capital Market is a major milestone for the
company and a testament to the significant progress Aptose has achieved
in the past year,” said William G. Rice, Ph.D., Aptose’s Chairman,
President and Chief Executive Officer. “Moving forward, we believe the
listing will provide access to a broader range of investors and
opportunity for increased shareholder value.”

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed
to discovering and developing personalized therapies addressing unmet
medical needs in oncology. Aptose is advancing new therapeutics focused
on novel cellular targets on the leading edge of cancer research
coupled with companion diagnostics to identify the optimal patient
population for our products. The company’s small molecule cancer
therapeutics pipeline includes products designed to provide additive or
synergistic efficacy with existing anti-cancer therapies and regimens
without overlapping toxicities. Aptose Biosciences Inc. is listed on
the TSX under the symbol APS and will be listed on NASDAQ under the
symbol APTO.

This press release contains forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements include,
but are not limited to, statements relating to Aptose’s plans,
objectives, expectations and intentions and other statements including
words such as “continue”, “expect”, “intend”, “will”, “should”,
“would”, “may”, and other similar expressions and including, without
limitation, statements regarding the listing date of Aptose’s common
shares on NASDAQ and the expected benefits to be derived from the
listing. Such statements reflect our current views with respect to
future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to significant
business, economic, competitive, political and social uncertainties and
contingencies. Many factors could cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements described in this press release. Such
expressed or implied factors include, among others: changes in our
stock price; our ability to meet listing requirements; our ability to
obtain the capital required for research and operations; the inherent
risks in early stage drug development including demonstrating efficacy;
development time/cost and the regulatory approval process; the progress
of our clinical trials; our ability to find and enter into agreements
with potential partners; our ability to attract and retain key
personnel; changing market conditions; stock market volatility; and
other risks detailed from time-to-time in our ongoing quarterly
filings, annual information forms, annual reports and annual filings
with Canadian securities regulators and the United States Securities
and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled “Risk Factors”
in our filings with Canadian securities regulators and the United
States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do not
intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure
you that such statements will prove to be accurate as actual results
and future events could differ materially from those anticipated in
such statements. Investors are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on forward-looking
statements due to the inherent uncertainty therein.

SOURCE Aptose Biosciences Inc.

PDF available at: http://stream1.newswire.ca/media/2014/10/21/20141021_C9026_DOC_EN_43076.pdf

Neurocrine Biosciences, Inc. Announces Initiation Of Phase 3 Study For VMAT2 Inhibitor NBI-98854

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double…

Contract Research Organization Announces Clinical Trial Patient Rescue Program With A Pay-Per-Patient Enrolled Pricing Structure

October 21, 2014 – 5:00 am | Edit Post

COSTA MESA, Calif., Oct. 21, 2014 /PRNewswire-iReach/ — WCCT Global, a full service contract research organization headquartered in Southern California announced today the launch of a clinical trial patient recruitment…

Immunotech Laboratories Enters Into Agreement To Market Potential Ebola Virus Disease (???EVD???) Treatment And Implement Strategy For Company’s ITV-1 Infectious Diseases Treatment In Africa

October 21, 2014 – 5:00 am | Edit Post

MONROVIA, Calif.–(BUSINESS WIRE)–Immunotech Laboratories, Inc. (OTC PINK: IMMB) (Immunotech or the Company) and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to…

Illumina, Inc. Reports Record Financial Results For Third Quarter Of Fiscal Year 2014

October 21, 2014 – 5:00 am | Edit Post

Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of $481 million, a 35% increase compared to $357 million in the third quarter of 2013 Help employers find you! Check out all the jobs and…

Ivera Medical Corporation Successfully Completes FDA Inspection

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – Oct 21, 2014) – Ivera Medical Corporation is pleased to report that it successfully completed several days of an exhaustive and intensive review by the Food and Drug Administration (FDA) of Ivera’s manufacturing practices, quality control and regulatory filings. At the conclusion of the inspection, which was prompted by a complaint filed by a competitor (Catheter Connections…

Cytori Therapeutics, Inc. Announces Resignation Of Effective November 1, 2014

October 21, 2014 – 5:00 am | Edit Post

The Board of Directors of Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Lloyd H. Dean has tendered his resignation as a member of the Board, effective November 1, 2014. Mr. Dean has served as a director of the Company since 2010 and served as Chairman of the Companys Board of Directors from April 2011 until June 2013. Help employers find you! Check out all the